Satellos shows fat-fraction drop, strength stability in 4 DMD adults on SAT-3247
Six-month TRAILHEAD data in four adults link SAT-3247 to reduced muscle fat and stable strength, but the interim readout carries no p-values and no comparator in a disease with no cure.
Executive Summary
- Satellos disclosed six-month follow-up data showing consistent movement across muscle-composition, effort, and strength measures in a small group of adults who had already been on the drug for months.
- The trial's registered primary endpoint is safety, not the efficacy measures the company highlighted, and the disclosed figures carry no statistical comparison against a control arm.
- SAT-3247 has no same-target comparator in Duchenne muscular dystrophy, so this readout is the only data point testing its specific mechanism in this disease so far.
- The company is expanding this open-label follow-up and moving a separate placebo-controlled pediatric study forward, which will be where any signal from this small cohort gets tested against a control group.
The readout
Satellos Bioscience, Inc. reported that all four adults enrolled in the TRAILHEAD extension study (NCT06867107) showed a decline in MRI-measured biceps fat fraction, from a mean of 49.7% at baseline to 46.0% at month 6, a 3.7-point drop the company framed as improved muscle composition. The same four participants showed a roughly 34% increase in TE99C, a wearable-device measure of maximum upper-limb effort, rising from 16.1 to 21.6 joules per kilogram over the same period. Handgrip strength gains recorded in the earlier 28-day CL-101 study, described as a near-doubling, were maintained through six months of TRAILHEAD follow-up, and mean creatine kinase, a blood marker of muscle damage, fell 38% from baseline. No serious treatment-emergent adverse events or discontinuations were reported, and Satellos said compliance was complete over an average 186 days of drug exposure. SatellosSatellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, ...Jul 8, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The design behind the numbers
TRAILHEAD is an open-label, single-arm extension study without a placebo or active comparator, enrolling adults who previously completed the Phase 1a/b CL-101 trial. Four of a target 10 participants have been analyzed at this interim point. The trial's registered primary endpoint is the incidence of treatment-emergent adverse events; muscle force, fat fraction, and functional measures are registered secondary endpoints. No p-values, confidence intervals, or primary-endpoint result have been posted to ClinicalTrials.gov for this study. NCT06867107An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101NCT06867107
A physician's read
Perry Shieh, a UCLA neurologist and pediatrics professor not employed by Satellos, said adults with Duchenne muscular dystrophy are among the hardest populations in which to detect a treatment effect given advanced muscle loss, fat infiltration, and depleted muscle stem cell reserves, and that the consistency across strength, composition, effort, and safety measures in this cohort is "potentially clinically meaningful" while noting the study is small. SatellosSatellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, ...Jul 8, 2026
Mechanism and the field
SAT-3247 targets AAK1, and no other industry trial in Duchenne muscular dystrophy shares that target, leaving this readout without a direct same-mechanism precedent. The broader Duchenne field includes small-molecule programs on different targets, such as Santhera's vamorolone and Italfarmaco's givinostat, and disease-modifying modalities including Sarepta's gene therapy and Dyne's oligonucleotide program, none of which test the same biology. Satellos is also running a separate placebo-controlled Phase 2 study of SAT-3247 in pediatric ambulatory patients (NCT07287189), targeting 51 participants with a primary completion date of March 2027, which will be the first controlled test of the drug's effects.
Timing and next steps
The trial's primary completion date has moved once, from June 30, 2026 to August 30, 2026, an amendment logged in May 2025 before enrollment began. Satellos said it remains on track to complete enrollment in a related study, BASECAMP, and to open US sites for TRAILHEAD in the third quarter of 2026. NCT06867107+1An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101NCT06867107Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, ...Jul 8, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.